Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) ( Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) ) online roadshow of convertible bond issuance was held on panorama on Wednesday afternoon Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) chairman and general manager Xie Xiaolin said in response to investors’ questions that the company has integrated R & D resources and built a “production, learning and research” platform with a number of university scientific research institutes inside and outside the province based on the company’s Pharmaceutical Research Institute, forming a close cooperative relationship. In the past two years, it has successfully developed 13 hospital preparations, 12 big health products, more than 200 traditional Chinese medicine formula particles, 3 classic prescriptions, 1 new traditional Chinese medicine and 3 chemical and generic drugs. Since 2020, it has been successfully approved as a national enterprise technology center and a demonstration institution for science and technology transfer, and the only hospital preparation centralized configuration service platform in Shaanxi Province. It has been rated as “top 50 enterprises in traditional Chinese medicine research and development” by the MI Nei network jury under the south.
In the later stage, the company will follow the strategy of “one body and two wings” in the research and development. In accordance with the research and development thought of “grasping the frontier and creating the combination of imitation”, we should adhere to the idea of “inheriting the essence and keeping the innovation”. We should take “specialization, refinement, specificity and new” as the starting point. First, we should continue to play the strengths of the company and expand the fruits in the development of medical preparations, classic prescriptions and dispensing granules. Highlight the characteristics of Panlong in the field of traditional Chinese medicine; Second, adhere to the development of new drugs in the field of rheumatic bone injury as a breakthrough, strive to put new products on the market as soon as possible, and enhance the core competitiveness of the company; Third, steadily enter the R & D field of biochemical products and biomedicine, mainly from the entry point of cardio cerebrovascular small molecule drugs and rheumatic immunotumor drugs, expand the strategic layout of the company’s pharmaceutical industry chain and improve the company’s anti risk ability; Fourth, strengthen the development of the company’s large-scale health products, enrich product categories, give full play to the advantages of the industrial chain, focus on the layout of health food in the direction of enhancing immunity and improving sleep, health products in the direction of dispelling wind and dehumidification and strengthening tendons and bones, and medical devices and functional food in the linkage of “medical beauty, medical treatment and medical maintenance”. In view of the above work, in the later stage, the company will increase scientific research investment and introduce high-end technical talents to fully promote the innovation work in the company.
